Criteria to define HLA haplotype loss in human solid tumors

被引：40

作者：

Ramal, LM

Feenstra, M

van der Zwan, AW

Collado, A

Lopez-Nevot, MA

Tilanus, M

Garrido, F

机构：

[1] Univ Granada, Hosp Univ Virgen Las Nieves, Dept Anal Clin, E-18014 Granada, Spain

[2] Univ Granada, Hosp Univ Virgen Las Nieves, Unidad Invest, E-18014 Granada, Spain

[3] Univ Med Ctr, Dept Pathol, Utrecht, Netherlands

来源：

TISSUE ANTIGENS | 2000年 / 55卷 / 05期

关键词：

HLA; tumor; loss of heterozygosity; short tandem repeat markers; STR;

D O I：

10.1034/j.1399-0039.2000.550507.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Short tandem repeat (STR) markers are currently used to define loss of heterozygosity (LOH) of genes and chromosomes in tumors. Chromosome 6 and chromosome 15 STR markers are applied to define loss of HLA and related genes (e.g. TAP and beta(2)m) The number of STR identified in the HLA region is still increasing. In this study, seven representative STR markers covering the 6p/6q arms of chromosome 6 including the HLA region and two for chromosome 15 flanking the beta(2)m gene, were selected as minimally required for reliable LOH studies. A multiplex polymerase chain reaction (PCR) strategy is proposed when small number of cells are available in microdissected tumor samples.

引用

页码：443 / 448

页数：6

共 12 条

[1] Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides [J].

Benitez, R ;

Godelaine, D ;

Lopez-Nevot, MA ;

Brasseur, F ;

Jiménez, P ;

Marchand, M ;

Oliva, MR ;

van Baren, N ;

Cabrera, T ;

Andry, G ;

Landry, C ;

Ruiz-Cabello, F ;

Boon, T ;

Garrido, F .

TISSUE ANTIGENS, 1998, 52 (06) :520-529

[2] HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas [J].

Feenstra, M ;

Veltkamp, M ;

van Kuik, J ;

Wiertsema, S ;

Slootweg, P ;

van den Tweel, J ;

de Weger, R ;

Tilanus, M .

TISSUE ANTIGENS, 1999, 54 (03) :235-245

[3] NATURAL-HISTORY OF HLA EXPRESSION DURING TUMOR-DEVELOPMENT [J].

GARRIDO, F ;

CABRERA, T ;

CONCHA, A ;

GLEW, S ;

RUIZCABELLO, F ;

STERN, PL .

IMMUNOLOGY TODAY, 1993, 14 (10) :491-499

[4] Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].

Garrido, F ;

RuizCabello, F ;

Cabrera, T ;

PerezVillar, JJ ;

LopezBotet, M ;

DugganKeen, M ;

Stern, PL .

IMMUNOLOGY TODAY, 1997, 18 (02) :89-95

[5] HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story [J].

Hicklin, DJ ;

Marincola, FM ;

Ferrone, S .

MOLECULAR MEDICINE TODAY, 1999, 5 (04) :178-186

[6]

Jiménez P, 1999, INT J CANCER, V83, P91, DOI 10.1002/(SICI)1097-0215(19990924)83:1<91::AID-IJC17>3.3.CO

[7]

2-W

[8] HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines [J].

Koopman, LA ;

Mulder, A ;

Corver, WE ;

Anholts, JDH ;

Giphart, MJ ;

Claas, FHJ ;

Fleuren, GJ .

TISSUE ANTIGENS, 1998, 51 (06) :623-636

[9]

Real LM, 1998, INT J CANCER, V75, P317, DOI 10.1002/(SICI)1097-0215(19980119)75:2<317::AID-IJC23>3.3.CO

[10]

2-8

← 1 2 →